Annexin Pharmaceuticals AB (OSTO:ANNX) Pretax Margin %: % (As of Mar. 2026)


OSTO:ANNX Annexin Pharmaceuticals AB OSTO:ANNX
23 GF Score
Price kr12.15
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB Pretax Margin %?

Annexin Pharmaceuticals AB OSTO:ANNX -3.19% 23 Pretax Margin % is % as of Mar. 2026. GuruFocus rates OSTO:ANNX with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Annexin Pharmaceuticals AB ranks worse than 105932.1% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Annexin Pharmaceuticals AB's Pre-Tax Income for the three months ended in Mar. 2026 was kr-10.52 Mil. Annexin Pharmaceuticals AB's Revenue for the three months ended in Mar. 2026 was kr0.00 Mil. Therefore, Annexin Pharmaceuticals AB's pretax margin for the quarter that ended in Mar. 2026 was %.

The historical rank and industry rank for Annexin Pharmaceuticals AB's Pretax Margin % or its related term are showing as below:


OSTO:ANNX's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.5
* Ranked among companies with meaningful Pretax Margin % only.

Annexin Pharmaceuticals AB  (OSTO:ANNX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Annexin Pharmaceuticals AB Pretax Margin % Related Terms


Annexin Pharmaceuticals AB Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Annexin Pharmaceuticals AB's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annexin Pharmaceuticals AB Pretax Margin % Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Annexin Pharmaceuticals AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OSTO:ANNX vs VRTX, REGN, ALNY: Pretax Margin % Comparison

For the Biotechnology subindustry, Annexin Pharmaceuticals AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annexin Pharmaceuticals AB Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexin Pharmaceuticals AB's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Annexin Pharmaceuticals AB's Pretax Margin % falls into.


OSTO:ANNX
23GF Score
Annexin Pharmaceuticals AB OSTO:ANNX
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Annexin Pharmaceuticals AB's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-36.893/0
= %

Annexin Pharmaceuticals AB's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-10.516/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Annexin Pharmaceuticals AB and its competitors. According to the industry distribution chart, Annexin Pharmaceuticals AB ranks #999999 out of 944 companies in the Biotechnology industry.
Is Annexin Pharmaceuticals AB's Pretax Margin % too high?
Annexin Pharmaceuticals AB's current Pretax Margin % is %. Based on the distribution chart, Annexin Pharmaceuticals AB ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annexin Pharmaceuticals AB ranks #999999 out of 944 companies for Pretax Margin %. This places Annexin Pharmaceuticals AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Annexin Pharmaceuticals AB and its competitors. Annexin Pharmaceuticals AB's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a current Pretax Margin % of %. The current Pretax Margin % is %. Annexin Pharmaceuticals AB's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (OSTO:ANNX), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annexin Pharmaceuticals AB Business Description

Other Exchanges Q910:Germany
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
23GF Score

Get the complete analysis for OSTO:ANNX

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.15
Price